Optimizing Treatment Selection and Side Effect Management in BRAF-Mutant Melanoma - a podcast by ReachMD

CME credits: 1.00

Valid until: 21-11-2022

Claim your CME credit at https://reachmd.com/programs/cme/optimizing-treatment-selection-and-side-effect-management-braf-mutant-melanoma/13042/

Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.

In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD